Ariana Motaghiannezam
Palo Alto,USA
Summary
Strategic business capital analyst specialized in the biotech therapeutic field. Expertise in market analysis and investment strategies, equipped with data interpretation and risk management skills, to optimize investment outcomes.
Overview
3
3
years of professional experience
Work History
Undergraduate Research Assistant (Chemistry)
Stanford University, Humanities and Sciences
Palo Alto, USA
06.2025 - 10.2025
- Explored the role of glycans in brain development and aging
Research Intern (Neurobiology)
Stanford University, School of Medicine
Palo Alto, USA
06.2025 - 10.2025
- Research on the role of ultra-rare protein-coding risk genes for neuropsychiatric disorders in brain development and aging (in collaboration with Dr. Ritchie Chen at UCSF)
Biotech Ventures Research Intern
BioFund Ventures Startup
Szeged, Hungary
02.2024 - 10.2025
- Developed a business pathway to commercialize a cancer drug: market analyses, clinical trial designs, regulatory strategies to ensure compliance and successful market entry, exit and partnership strategies
Research Intern (Cancer Biology and Bioinformatics)
Stanford University, School of Medicine
Palo Alto, USA
01.2023 - 10.2024
- Submitted 1 paper to journal of hepatology & 3 papers under preparation to oncology and science journals
- Presented 7 posters at Stanford research retreats and symposium as well as county, state, and international fairs
- Contributed to a $250k grant application to Stanford HIT Fund
- Research on liver and lung fibrosis and cancerous diseases
- Research on novel immunotherapy targets for therapeutic application
- Research on identifying molecular targets for obesity
- Research on exploring the roles of CD63, CD47, and CAR-T cells for liver & lung cancers and metabolic disorders
Education
Bachelor of Science - Bioengineering/Management Science and Engineering
Stanford University
Palo Alto, CA02.2026
Skills
- Java
- Market research & competitive landscape analysis
- Customer segmentation & stakeholder interviews
- Go-to-market strategy
- Regulatory pathway analysis
- Business development & partnership evaluation
- Commercialization strategy for therapeutic products
- Grant writing & funding strategy
- Financial modeling & cost-benefit analysis
Publications
- C. De Souza, Ariana Motaghiannezam, et al., Targeting the AP1-CD47 Axis for the Treatment of Obesity and other Metabolic Syndromes, PNAS, Under-preparation, 2025
- C. De Souza, Ariana Motaghiannezam, et al., Elucidating the Role of the Innate Immune Milieu in Driving Desmoid Fibromatosis, Lancet Oncology, Under-preparation, 2025
- Ariana Motaghiannezam, C. De Souza, et al., Understanding the Myriad Molecular Mechanisms Driving Pathogenic Fibrosis, Cancers, Under-preparation, 2025
- C. De Souza, Ariana Motaghiannezam, et al., Targeting CD63 as a novel 'don't eat me' signal for the treatment of NASH and HCC, Journal of Hepatology, Submitted, 2024
- C. De Souza, Ariana Motaghiannezam, et al., Identifying Novel Immune Targets for the Treatment and Reversion of Pathogenic Fibrosis, Stanford Pathology Research Retreat 2024, Stanford, 10/01/24
- C. De Souza, Ariana Motaghiannezam, et al., Targeting Novel Immune Modulatory Protein for Treating Fibrotic Pathologies, Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program Symposium, Stanford, 08/01/24
- Ariana Motaghiannezam, Multi-omic Profiling IDs p63 as a Novel Genetic Determinant Driving Lung Fibrosis and Cancer, Targetable for Treatment, Regeneron International Science and Engineering Fair (ISEF), Los Angeles, 05/01/24
- Ariana Motaghiannezam, Multi-omic Profiling IDs p63 as a Novel Genetic Determinant Driving Lung Fibrosis and Cancer, Targetable for Treatment, Virtual Presentation at California Science & Engineering Fair, 04/01/24
- Ariana Motaghiannezam, Multi-omic Profiling IDs p63 as a Novel Genetic Determinant Driving Lung Fibrosis and Cancer, Targetable for Treatment, Santa Clara Valley Science & Engineering Fair, San Jose, 03/01/24
- C. De Souza, Ariana Motaghiannezam, et al., Targeting CD63 as a Novel Fibrogenic Immune Target for the Treatment of HCC and NASH, Stanford Pathology Research Retreat 2023, Stanford, 11/01/23
- Ariana Motaghiannezam, C. De Souza, et al., Targeting CD63 as a Novel Fibrogenic Immune Target for the Treatment of HCC and NASH, 15th Annual Stanford Institute for Stem Cell Biology and Regenerative Medicine Retreat, Santa Cruz, 09/01/23
Honors And Awards
- Pars Youth Grant Scholarship Award, $2000, National, 08/01/25
- City of Mountain View Certificate of Recognition for Synopsys Science Fair Champion, City, 02/01/25
- Health Disparity Award of 2024 Stanford Pathology Research Retreat, City, 10/01/24
- Finalist at Regeneron International Science-Engineering Fair (ISEF), The world's largest pre-college STEM competition, International, 05/01/24
- First Place Sponsored Scholar Award, $2000, Granted the highest senior division scholar prize for supporting health research and social welfare, State, 04/01/24
- Grand Prize - Best of Championship - Biological Sciences at Santa Clara Valley Science and Engineering Fair, County, 04/01/24
- First Award - RRI Biological Science and Engineering in Santa Clara Valley Science & Engineering Fair, County, 04/01/24
- Basic Research Award of the 2023 Stanford Pathology Research Retreat, City, 11/01/23
- 2nd Ranked Poster Award at 15th Annual Stanford Institute for Stem Cell Biology & Regenerative Medicine, City, 09/01/23
Timeline
Undergraduate Research Assistant (Chemistry)
Stanford University, Humanities and Sciences
06.2025 - 10.2025
Research Intern (Neurobiology)
Stanford University, School of Medicine
06.2025 - 10.2025
Biotech Ventures Research Intern
BioFund Ventures Startup
02.2024 - 10.2025
Research Intern (Cancer Biology and Bioinformatics)
Stanford University, School of Medicine
01.2023 - 10.2024
Bachelor of Science - Bioengineering/Management Science and Engineering
Stanford University